586 F.Supp.3d 231
S.D.N.Y.2022Background
- Pfizer voluntarily recalled Chantix after FDA found N-nitroso‑varenicline (a nitrosamine classified as possibly carcinogenic) above acceptable intake levels; recall expanded to all lots by September 2021.
- FDA had initially set 37 ng/day acceptable intake, raised an interim level to 185 ng/day to avoid shortages; Pfizer expanded recalls when levels exceeded the interim limit.
- Plaintiffs Roslyn Harris (NJ) and Mary Allen (NY) purchased and consumed recalled Chantix, paid co‑pays, but allege no physical or emotional injury—only economic loss.
- Plaintiffs claim they would not have purchased Chantix had they known about contamination and seek class damages under fraud, consumer‑protection statutes, express and implied warranty, negligent misrepresentation, and unjust enrichment.
- Pfizer moved to dismiss under Fed. R. Civ. P. 12(b)(1) and 12(b)(6); Court exercised CAFA jurisdiction and granted Pfizer’s motion, dismissing the FAC for failure to state plausible claims.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Standing | Plaintiffs: economic overpayment for a defective product confers Article III injury. | Pfizer: plaintiffs got the product and benefit; no cognizable injury. | Plaintiffs have standing—economic price‑difference is a concrete injury. |
| Fraud (affirmative misrepresentation & omission) | Plaintiffs: Pfizer misled by labeling and failing to disclose nitrosamine contamination; would have relied. | Pfizer: label accurately identified Chantix/varenicline; no duty to disclose; no knowledge of contamination at purchase; Rule 9(b) not met. | Fraud claims dismissed—no actionable misrepresentation, no duty to disclose, insufficient facts showing Pfizer’s knowledge/intent. |
| Consumer‑protection statutes (NJCFA and NY GBL) | Plaintiffs: nondisclosure and labeling were deceptive and materially misleading to consumers. | Pfizer: statements were not misleading; no superior knowledge or proof Pfizer knew of contamination when purchases occurred. | Claims dismissed—allegations do not plausibly show Pfizer knew of contamination or made materially misleading statements/omissions. |
| Express and implied warranties | Plaintiffs: Chantix was warranted as safe/fit and free from contamination; contamination breached express and implied warranties. | Pfizer: presence of contaminant does not change the product identity; no express warranty of absolute purity; Allen lacks privity for implied warranty; product remained fit for intended use. | Warranty claims dismissed—no express warranty of nitrosamine‑free product; implied warranty fails (privity for Allen and no plausible breach given product’s fitness and FDA guidance). |
| Negligent misrepresentation & unjust enrichment | Plaintiffs: relied on Pfizer’s statements/labels and seek restitution. | Pfizer: economic‑loss doctrine bars negligent tort; no special relationship; unjust enrichment duplicates contract claims. | Both claims dismissed—economic‑loss doctrine, lack of independent duty/special relationship, and unjust enrichment duplicative. |
Key Cases Cited
- Spokeo, Inc. v. Robins, 578 U.S. 330 (2016) (Article III injury‑in‑fact framework)
- Melito v. Experian Marketing Sols., 923 F.3d 85 (2d Cir. 2019) (standing elements summary)
- Dubuisson v. Stonebridge Life Ins. Co., 887 F.3d 567 (2d Cir. 2018) (economic overpayment as concrete injury)
- Bell Atlantic Corp. v. Twombly, 550 U.S. 544 (2007) (plausibility standard for Rule 12(b)(6))
- Ashcroft v. Iqbal, 556 U.S. 662 (2009) (pleading standards and inference drawing)
- Loreley Fin. (Jersey) No. 3 Ltd. v. Wells Fargo Sec., LLC, 797 F.3d 160 (2d Cir. 2015) (fraud pleading particularity and strong‑inference requirement for intent)
- Remington Rand Corp. v. Amsterdam‑Rotterdam Bank, N.V., 68 F.3d 1478 (2d Cir. 1995) (when a duty to disclose arises)
- Bellevue S. Assocs. v. HRH Constr. Corp., 78 N.Y.2d 282 (N.Y. 1991) (economic‑loss doctrine and privity for implied warranty)
- Oswego Laborers’ Local 214 Pension Fund v. Marine Midland Bank, N.A., 85 N.Y.2d 20 (N.Y. 1995) (material omission standard under NY GBL §349)
- Basko v. Sterling Drug, Inc., 416 F.2d 417 (2d Cir. 1969) (express warranty does not guarantee a drug is completely harmless)
- Elk Grove Unified School Dist. v. Newdow, 542 U.S. 1 (2004) (distinguishing standing from merits inquiry)